This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.
Drug: OFEV
twice daily
Inclusion Criteria:
None
Exclusion Criteria:
- Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary
Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation
in this Expanded Access Program (EAP).
Banner University Medical Center Tucson
Tucson, Arizona, United States
The Lung Research Center, LLC
Chesterfield, Missouri, United States
Glacier View Research Institute
Kalispell, Montana, United States
University of Rochester Medical Center
Rochester, New York, United States
Centra Medical Group
Bedford, Virginia, United States
Inova Fairfax Medical Campus
Falls Church, Virginia, United States